S-1/A: Processa Pharmaceuticals Announces Public Offering of Common Stock and Warrants to Fund Cancer Drug Development

Processa Pharmaceuticals is launching a public offering to raise capital for a Phase 2 clinical trial of its NGC-Cap drug and for general corporate purposes.

Summary

• Processa Pharmaceuticals is offering up to 1,750,000 shares of common stock and accompanying common warrants, as well as pre-funded warrants as an alternative to common stock for certain purchasers.
• The assumed combined public offering price is $4.00 per share and accompanying common warrant, based on the last sale price of the common stock on January 18, 2024.
• The common warrants have an exercise price equal to 100% of the combined public offering price and will be exercisable upon stockholder approval or immediately if certain pricing conditions are met, expiring five years from the initial exercise date.
• Pre-funded warrants are offered to purchasers who would otherwise exceed beneficial ownership limits, exercisable at $0.0001 per share and expiring when exercised in full.
• The offering will terminate on February 2, 2024, unless terminated earlier, and H.C. Wainwright & Co., LLC is acting as the exclusive placement agent.
• The company intends to use the net proceeds to begin a Phase 2 clinical trial of NGC-Cap and for working capital and other general corporate purposes.
• The company estimates net proceeds of approximately $6.2 million from the offering, which, along with existing cash, is expected to fund operations into early 2025.
• A one-for-twenty reverse stock split was effective on January 22, 2024.
• The company is a smaller reporting company and has elected to comply with certain reduced public company reporting requirements.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company is raising capital for a promising drug candidate, it also faces financial challenges and risks associated with the offering.

Positives

• The offering will provide capital to advance the Phase 2 clinical trial of NGC-Cap, a key drug in Processa's pipeline.
• The company has flexibility in the use of proceeds, allowing it to allocate funds to the most promising opportunities.
• The offering includes pre-funded warrants, providing an option for investors who may be limited by beneficial ownership restrictions.
• The company believes that the net proceeds from this offering, together with our cash on hand, will satisfy our capital needs into early 2025 based on our current business plan.

Negatives

• The offering is being made on a best-efforts basis, and the company may not raise the full amount of capital it seeks.
• There is no established public trading market for the pre-funded warrants or the common warrants, and we do not expect a market to develop.
• The company has incurred recurring losses since inception and had an accumulated deficit of approximately $73.0 million as of September 30, 2023.
• The company expects continued operating losses and negative cash flow from operations for the foreseeable future.

Risks

• The company needs to raise additional capital to fund its operations and continue its planned development of its NGC drugs.
• The company's estimates of the amount of cash necessary to fund its activities may prove to be wrong and it could spend its available financial resources much faster than it currently expects.
• The company may be subject to delisting from the Nasdaq Capital Market if it fails to regain compliance with continued listing requirements.
• The company does not anticipate paying any cash dividends on its common stock in the foreseeable future.
• The market price of the common stock may fluctuate significantly.

Future Outlook

The company believes that the net proceeds from this offering, together with its cash on hand, will satisfy its capital needs into early 2025 based on its current business plan. In early 2025, the company will need to raise additional capital to fund its operations and continue its planned development of its NGC drugs.

Industry Context

The announcement reflects a common strategy for clinical-stage biopharmaceutical companies to raise capital to fund ongoing research and development activities, particularly for promising drug candidates in the oncology space. The focus on Next Generation Chemotherapy (NGC) aligns with the industry's trend toward developing more targeted and effective cancer treatments.

Comparison to Industry Standards

• The decision to pursue a public offering to fund a Phase 2 clinical trial is a standard practice in the biopharmaceutical industry, comparable to companies like Celldex Therapeutics and Geron Corporation, which have also utilized public offerings to advance their clinical programs.
• The offering structure, including common stock, pre-funded warrants, and common warrants, is similar to those employed by other small-cap biotech companies such as XOMA Corporation and BioCryst Pharmaceuticals to attract a broader range of investors.
• The engagement of H.C. Wainwright & Co., LLC as the exclusive placement agent is consistent with industry norms, as H.C. Wainwright is a well-known investment bank specializing in the life sciences sector, similar to Jefferies and SVB Securities.
• The estimated net proceeds of $6.2 million are relatively modest compared to larger offerings by more established pharmaceutical companies, but are typical for smaller, clinical-stage companies focused on niche therapeutic areas.

Stakeholder Impact

• Shareholders may experience dilution as a result of the offering.
• Employees may benefit from the company's ability to fund its operations and continue its development programs.
• Patients may benefit from the development of new and improved cancer treatments.
• Creditors may be impacted by the company's use of proceeds and its ability to repay its debts.

Next Steps

• The company will begin a Phase 2 clinical trial of NGC-Cap.
• The company will continue to develop its pipeline of NGC proprietary small molecule oncology drugs.
• The company will explore options to monetize its non-core drug assets.
• The company will need to raise additional capital in early 2025 to fund its operations.

Key Dates

Keywords

public offering, common stock, warrants, pre-funded warrants, NGC-Cap, clinical trial, Processa Pharmaceuticals, capital raise, oncology, pharmaceuticals